Year: 2022
BerGenBio Reports Third Quarter 2022 Financial Results and Provides Business Update
November 15, 2022
- Randomized first patient in the Phase 2b EU-SolidAct platform for hospitalized COVID-19 patients --…
Read MoreBerGenBio Announces Initiation of Phase 1b/2a Trial Evaluating Bemcentinib in 1st line Non-Small Cell Lung Cancer Patients Harboring STK11 Mutations
October 11, 2022
- Study will assess bemcentinib in combination with current standard of care for 1st line…
Read MoreBERGENBIO ANNOUCES FIRST PATIENT RANDOMIZED IN BEMCENTINIB TRIAL IN EU-SOLIDACT PLATFORM FOR HOSPITALIZED COVID-19 PATIENTS
September 27, 2022
BERGEN, Norway, September 27, 2022 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharma-ceutical company developing…
Read MoreBerGenBio Reports Second Quarter and Half Year 2022 Financial Results and Provides Business Update
August 23, 2022
- Commenced bemcentinib Phase 2b trial in hospitalized COVID-19 patients - - Initiation of Phase…
Read MoreBERGENBIO PRESENTS CLINICAL DATA ON BEMCENTINIB IN COMBINATION WITH DOCETAXEL IN PATIENTS WITH PREVIOUSLY TREATED ADVANCED NSCLC AT ASCO ANNUAL MEETING 2022
June 6, 2022
Bergen, Norway, 6 June 2022 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective…
Read MoreBERGENBIO ASA: RESULTS FOR THE FIRST QUARTER 2022
May 24, 2022
Bergen, Norway, 24 May 2022 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing…
Read More
